Literature DB >> 32169203

Muscle protein anabolism in advanced cancer patients: response to protein and amino acids support, and to physical activity.

S Antoun1, B Raynard2.   

Abstract

In the field of oncology, it is well recognized that a decrease in mass, density, strength, or function of skeletal muscle is associated to increased treatment toxicities and postoperative complications, as well as poor progression-free survival and overall survival. The ability of amino acids to stimulate protein synthesis in cancer patients is reduced. Considering nutritional intervention, this anabolic resistance could be in a part counteracted by increasing protein or by giving specific amino acids. In particular, Leucine might counteract this anabolic resistance not only by increasing substrate availability, but also by directly modulating the anabolic signal pathway. Few studies showed the possibility of increasing muscle protein synthesis by specific nutriments and/or by increasing amino acids or protein administration. In addition, whereas many studies provide evidence of a benefit of adapted physical activity in advanced cancer patients, it is difficult to specify the most appropriate type of exercise, and the optimum rhythm and intensity. Moreover, the benefits of physical activities and of protein support seem greater when it is started at the precachexia stage rather than at the cachexia stage, and their benefits are limited or nonexistent at the stage of refractory cachexia. Future approaches should integrate the combination of several complementary treatments in order to prevent (or improve) cachexia and/or sarcopenia in cancer patients.
© 2018 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cachexia; muscle; physical activity; protein anabolism; sarcopenia

Year:  2019        PMID: 32169203     DOI: 10.1093/annonc/mdx809

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  1 in total

1.  Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma.

Authors:  Emeline Colomba; Carolina Alves Costa Silva; Gwénaël Le Teuff; Jamie Elmawieh; Daniel Afonso; Axelle Benchimol-Zouari; Annalisa Guida; Lisa Derosa; Ronan Flippot; Bruno Raynard; Bernard Escudier; François Bidault; Laurence Albiges
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-07-28       Impact factor: 12.063

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.